NLS Pharmaceutics Presents Latest Clinical and Preclinical Data at SLEEP 2023

Oral presentation sharing significant phase 2 results of Mazindol ER in Adults with Narcolepsy Type 1 and Type 2Five abstracts demonstrating NLS focus on and investment in hypersomnia disorders and rare and complex neurologic diseasesZURICH, …